Article
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.
Nature genetics - 1 Mar 2026
Chan Irenaeus C C, Zhang Pu, Pan Xiangyu, Castro Cynthia, Fox Nina, Lewis Alexander M, Weis Kenyon, Cuibus Adriana, Tittley Steven, Petrone Giulia, Beeler J Scott, Tran Duc, Mustion Griffen, Fronick Catrina, Stopsack Konrad H, Cruchaga Carlos, Abdel-Wahab Omar, Bolton Kelly L
Abstract excerpt
Therapy-related myeloid neoplasm (tMN) is a fatal consequence of exposure to cytotoxic therapy administered in the treatment of cancer. Individuals with pre-existing TP53 clonal hematopoiesis (CH) are at high risk of tMN, with avoidance of therapy being the only strategy to reduce tMN risk. Here, in four randomized clinical trials, we show that the CDK4/6 inhibitor trilaciclib, given in conjunction with a variety...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.